Sarah Cannon Research Institute Implements Virtify CTRR Clinical Trial Disclosure Solution Improves Compliance, Productivity, Cost Savings
LEXINGTON, Mass., July 15, 2013 /PRNewswire/ -- Virtify, Inc., a leading innovator in content and regulatory information management solutions for the life science industry, today announced that Sarah Cannon Research Institute (SCRI), a wholly owned subsidiary of HCA, has signed an enterprise-level contract for its Clinical Trial Registration & Results (CTRR) disclosure software. SCRI will utilize Virtify's CTRR to disclose their clinical trial information to the National Institute of Health's clinicaltrials.gov system as mandated by federal regulation.
The old paradigm for managing disclosure throughout the clinical trial process has changed, including at academic and research organizations. Many now recognize that the large number of disparate, investigator-driven studies at these institutions, coupled with constant updates to these studies and increasingly complex disclosure requirements, render manual processes too cumbersome and error-prone.
"Sarah Cannon Research Institute is pleased to partner with Virtify to help automate the clinical trial disclosure processes within the SCRI Services Organization in order to fulfill its regulatory requirements," said Sheetal Khedkar, M.D., M.S.P.H, Director for Pharmacovigilance, Medical Writing and Scientifics at SCRI. "Virtify CTRR will help automate registration and results posting, significantly reducing the effort it takes to publish the trial information to clinicaltrials.gov."
Virtify's CTRR software helps streamline and automate the mandatory registration and results disclosure postings to the clinicaltrials.gov website and to other registries. The software also has the ability to provide a compliance view across all studies at an institution, allowing for better reporting and proactive compliance. Virtify's CTRR software offers academic/research institutions the most complete overall solution for managing compliance with regulatory reporting requirements including supporting integrations to "Off the Shelf" or custom applications.
"Virtify's CTRR system will enable SCRI to comply with clinical disclosure requirements in an efficient, consistent and predictable manner," said Satish Tadikonda, President and CEO of Virtify, Inc. "Simultaneously, Virtify CTRR will help streamline and optimize their disclosure activities, resources, and time. This increases business efficacy and productivity. The ability of Virtify CTRR to communicate with other SCRI systems means that duplicate data entry can be eliminated as well."
Sarah Cannon Research Institute (SCRI) is a global strategic research organization focusing on advancing therapies for patients. It is one of the largest clinical research programs, conducting community-based clinical trials in oncology and cardiology through affiliations with a network of more than 700 physicians in the United States and United Kingdom. Additionally, SCRI offers management, regulatory and other research support services to drug development sponsors and strategic investigator sites. SCRI is a wholly owned subsidiary of HCA. For more information, please visit http://sarahcannonresearch.com/
Virtify is the leading innovator in content and regulatory information management solutions for life sciences. Many of the world's leading organizations rely on Virtify solutions to reduce time-to-market, risk, and costs by managing and automating the complex regulatory compliance and content exchange requirements throughout the product life cycle. Virtify's life science domain expertise has been leveraged by such companies as Genzyme/Sanofi, Novartis, Pfizer/Wyeth, Regeneron, academic research centers and CROs. Virtify's easy-to-use software suite is the industry's only solution to provide a secure, collaborative, web-based environment for managing regulated content throughout the entire continuum – from pre-clinical through product registration to commercialization. Visit us at http://www.virtify.com
SOURCE Virtify, Inc.